FLAG Therapeutics develops cancer therapeutics using new classes of small molecules which have selective dual activity: antiangiogenesis and chemotherapeutic.
Employment range in NC
Primary site activity
All company activities
Products under development
FLAG-003, a small molecule which has anti-angiogenic and anti-tubulin properties for the treatment of Glioma. FLAG also has a series of compounds which are GARFTase and SHMT-2 inhibitors, which are First-in-Class purine synthesis inhibitors.